Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

2768445-19-6Upadacitinib Trifluoroacetamide Impurity

● In Stock

Catalogue No.:	VE0027858
CAS No.:	2768445-19-6
Mol. Formula:	C23H22F3N5O3S
Mol. Weight:	505.51 g/mol

Request a quote

Add to RFQ list

Additional information on CAS 2768445-19-6

Parent drug

Upadacitinib

IUPAC Name

1-((3S,4R)-3-ethyl-4-(3-tosyl-3H-imidazo[1,2-a]pyrrolo [2,3-e]pyrazin-8-yl) pyrrolidin-1- yl)-2,2,2-trifluoroethanone

Pharmacopeial Synonyms

N/A

Synonyms

N/A

Smiles

FC(F)(F)C(N1C[C@@H](CC)[C@@H](C2=CN=C3C=NC(N(S(=O)(C4=CC=C(C)C=C4)=O)C=C5)=C5N32)C1)=O

InChI

InChI=1S/C23H22F3N5O3S/c1-3-15-12-29(22(32)23(24,25)26)13-17(15)19-10-27-20-11-28-21-18(31(19)20)8-9-30(21)35(33,34)16-6-4-14(2)5-7-16/h4-11,15,17H,3,12-13H2,1-2H3/t15-,17+/m1/s1

Description

Upadacitinib Trifluoroacetamide Impurity (CAS 2768445-19-6) is a process-related byproduct formed during trifluoroacetylation steps in Upadacitinib synthesis, requiring targeted analytical characterization and control. This impurity exhibits distinct mass and 19F NMR signatures enabling detection by LC-MS and fluorine-sensitive NMR methods, while HPLC with appropriate reference standards supports quantitation. Relevant quality considerations include establishment of identification thresholds, qualification limits per ICH Q3A/B, forced degradation studies to assess stability, and implementation of purification or process adjustments to minimize carryover. Accurate profiling of this impurity is essential for regulatory submissions and consistent drug substance quality.